Jeffrey N. Simmons - 01 Mar 2026 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role: PRESIDENT, CEO AND DIRECTOR, Director
Signature: /s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons
Issuer symbol: ELAN
Transactions as of: 01 Mar 2026
Net transactions value: -$6,071,525
Form type: 4
Filing time: 03 Mar 2026, 19:18:37 UTC
Previous filing: 24 Feb 2026
Next filing: 05 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Simmons Jeffrey N	PRESIDENT, CEO AND DIRECTOR, Director	C/O ELANCO ANIMAL HEALTH INCORPORATED, 450 ELANCO CIRCLE, INDIANAPOLIS	/s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons	03 Mar 2026	0001479079

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELAN	Common Stock	Award	$0	+397,041	+22%	$0.000000	2,200,459	01 Mar 2026	Direct	F1
transaction	ELAN	Common Stock	Tax liability	$6,071,525	-229,982	-10%	$26.40	1,970,477	01 Mar 2026	Direct
transaction	ELAN	Common Stock	Award	$0	+119,319	+6.1%	$0.000000	2,089,796	01 Mar 2026	Direct	F2
holding	ELAN	Common Stock						167,000	01 Mar 2026	By Revocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELAN	Employee Stock Option (right to buy)	Award	$0	+243,809		$0.000000	243,809	01 Mar 2026	Common Stock	243,809	$26.40	Direct	F3
transaction	ELAN	Deferred Stock Units (Match)	Award	$0	+6,593		$0.000000	6,593	01 Mar 2026	Common Stock	6,593		Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,038 shares acquired on January 31, 2026 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.
F2	Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.
F3	Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.
F4	Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
F5	Deferred stock units vest December 31, 2027 and settle upon termination of employment or otherwise in accordance with the Executive Deferral and Stock Match Plan.